Nyrada (ASX:NYR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Nyrada (ASX:NYR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Quarterly Activities Report and Appendix 4C
Nyrada advances Xolatryp trials, secures FDA support and raises AU$12 million
PROTECT-MI Phase IIa Clinical Trial Update No 3
Nyrada Receives Positive FDA Feedback
Nyrada receives supportive FDA feedback for Xolatryp Phase IIa pathway
Attaching Options Prospectus
Nyrada lodges prospectus for free attaching options with $0.93 exercise price
Securities Purchase Plan Offer Booklet
2026 AGM Letter to Shareholders, Notice of Meeting & Proxy
Nyrada US Patent for Xolatryp Granted
Cleansing Statement
Application for quotation of securities - NYR
Proposed issue of securities - NYR
Proposed issue of securities - NYR
Proposed issue of securities - NYR
Proposed issue of securities - NYR
Cap Raise Deck-Building the Future of TRPC-based Therapies
Nyrada launches A$14m capital raise to fund Phase IIa trial and expand TRPC drug pipeline
Nyrada Successfully Raises AU$12.0 Million Via Placement
Nyrada raises AU$12 million to advance Xolatryp clinical programs
Trading Halt
Investor Presentation- Evans&Partners Small Cap Healthcare
Change in substantial holding - M Azzi
Cleansing Statement
Application for quotation of securities - NYR
Xolatryp Demonstrates Cardioprotection in Preclinical Study
Nyrada's Xolatryp Shows Sustained Cardioprotection and Anti-Tumour Potential in Preclinical Doxorubicin Study
Nyrada Full Year Results FY2026
Nyrada advances Xolatryp clinical trials, expands oncology pipeline, strengthens IP, and reports solid FY2026 financials
Annual Report for year ended 30 June 2026
Nyrada advances Xolatryp clinical trials, expands pipeline, secures US patent, and strengthens financial position in FY2026
Preliminary Final Report
Nyrada Inc. reports increased loss and lower revenue for FY2026 with no dividends declared
Appendix 4G and Corporate Governance Statement
Change in substantial holding - M Azzi
CSANZ26 Conference Poster
Quarterly Activities Report and Appendix 4C
Nyrada advances Xolatryp Phase IIa trial, secures US patent allowance, and reports strong cash position
